.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01G_AminoglycosideAntibacterials.J01GB06_Amikacin.Amikacin

Information

Amikacin is an aminoglycoside antibiotic primarily used for the treatment of severe Gram-negative bacterial infections, including infections caused by multidrug-resistant organisms. It is usually reserved for hospital-acquired infections or when other antibiotics are ineffective. Amikacin is an approved drug and is included in the World Health Organization's List of Essential Medicines.

Pharmacokinetics

Pharmacokinetic parameters reported for adult subjects with normal renal function following single intravenous bolus dose administration.

References

1. Severino, N, et al., & Paredes, N (2023). Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis. British journal of clinical pharmacology 89(7) 2254–2262. DOI:10.1111/bcp.15697 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36811146

2. Medellín-Garibay, SE, et al., & García, B (2022). Amikacin pharmacokinetics in elderly patients with severe infections. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 175 106219–None. DOI:10.1016/j.ejps.2022.106219 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35618200

3. Bressolle, F, et al., & Gomeni, R (1996). Population pharmacokinetics of amikacin in critically ill patients. Antimicrobial agents and chemotherapy 40(7) 1682–1689. DOI:10.1128/AAC.40.7.1682 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8807062

Revisions

• 06/2025 initial generated model